All TIM-3 reagents are produced in house and quality controlled, including 9 TIM-3 Antibody, 2 TIM-3 ELISA, 13 TIM-3 Gene, 1 TIM-3 IPKit, 5 TIM-3 Lysate, 5 TIM-3 Protein, 1 TIM-3 qPCR. All TIM-3 reagents are ready to use.
Recombinant TIM-3 proteins are expressed by HEK293 Cells with fusion tags as C-human IgG1-Fc & His, C-His, C-human IgG1-Fc.
TIM-3antibodies are validated with different applications, which are ELISA, ELISA(Det), WB, IP, ELISA(Cap).
TIM-3cDNA clones are full length sequence confirmed and expression validated. There are 13 kinds of tags for each TIM-3 of different species, especially GFP tag, OFP tag, FLAG tag and so on. There are three kinds of vectors for choice, cloning vector, expression vector and lentivrial expression vector.
TIM-3ELISA Kit are quality controlled by 8 internation QC standard which guarantee every ELISA Kit with high quality.
Hepatitis A virus cellular receptor 2 (HAVCR2), formerly known as T cell immunoglobulin and mucin domain-3 (TIM-3), is a transmembrane glycoprotein expressed on the surface of terminally differentiated Th1 cells but not on Th2 cells. It was the first surface molecule that specifically identifies Th1 cells in both mice and human. Recently, identification of Galectin-9 as a ligand for TIM-3 has established the TIM-3-Galectin-9 pathway as an important regulator of Th1 immunity and tolerance induction. Engagement of Tim-3 by its ligand galectin-9 negatively regulates IFN-gamma secretion and influences the ability to induce T cell tolerance in both mice and man. It suggests a novel paradigm in which dysregulation of the TIM-3-galectin-9 pathway could underlie chronic autoimmune disease states, such as multiple sclerosis. Recent work has explored the role of TIM-3 in systemic lupus erythematosus (SLE), and their results indicate that TIM-3 may represent a novel target for the treatment of SLE. Numerous studies have demonstrated that Tim-3 influences autoimmune diseases, including diabetes and multiple sclerosis, and its role in other inflammatory diseases including allergies and cancer is beginning to become clear. In tumor rejection model, soluble form of Tim-3 (sTim-3) significantly impaired T cell antitumor immunity, evidenced by decreased antitumor CTL activity and reduced amount of tumor-infiltrating lymphocytes in tumor. sTim-3 as an immunoregulatory molecule that may be involved in the negative regulation of T cell-mediated immune response.
Immune Checkpoint Detection: ELISA Antibodies Immune Checkpoint Detection: IP Antibodies Immune Checkpoint Detection: WB Antibodies
Immune Checkpoint Proteins
Immune Checkpoint Targets Co-inhibitory Immune Checkpoint Targets